Escitalopram Impairs Thrombin-Induced Platelet Response, Cytoskeletal Assembly and Activation of Associated Signalling Pathways

Thrombosis and Haemostasis

Volumn 117, Issue 12, 2017, Pages 2312-2321

  Lopez Vilchez, Irene ^a   Jerez Dolz, Didac ^a   Diaz Ricart, Maribel ^a   Navarro, Victor ^a   Urooj Zafar, M ^b   Zamorano Leon, Javier ^c   Lopez Farre, Antonio ^c   Badimon, Juan J ^b   Gasto, Cristobal ^a   Escolar, Gines ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

cytoskeleton; platelet function; release of granules; selective serotonin reuptake inhibitor; thrombin

Indexed keywords

ACTIN BINDING PROTEIN; ALPHA ACTININ; ANTITHROMBOCYTIC AGENT; CD63 ANTIGEN; CYTOSKELETON PROTEIN; ESCITALOPRAM; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MYOSIN; PADGEM PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE C; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; THROMBIN; TROPOMYOSIN; CITALOPRAM; SEROTONIN UPTAKE INHIBITOR;

ACTIN FILAMENT; ACTIN POLYMERIZATION; ARTICLE; CONTROLLED STUDY; DENSITOMETRY; DEPOLYMERIZATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN ELECTROPHORESIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN POLYMERIZATION; SEROTONINERGIC NERVE CELL; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE RICH PLASMA; THROMBOCYTE STRUCTURE; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING; BLOOD CLOTTING PARAMETERS; CELL CULTURE; DRUG EFFECT; METABOLISM; NORMAL HUMAN; PHOSPHORYLATION; PHYSIOLOGY; THROMBOCYTE;

ACTIN CYTOSKELETON; BLOOD PLATELETS; CELLS, CULTURED; CITALOPRAM; HEALTHY VOLUNTEERS; HUMANS; PHOSPHORYLATION; PLATELET ACTIVATION; PLATELET FUNCTION TESTS; SEROTONIN UPTAKE INHIBITORS; SIGNAL TRANSDUCTION; THROMBIN;

EID: 85054476483     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH17-04-0288     Document Type: Article

References (47)

1. Escolar G. Díaz-Ricart M. Gomez-Gil E., et al. Serotonergic mechanisms: a potential link between affective disorders and cardiovascular risk. Drugs Today (Barc): 2005; 41 11 721 743
2. Seligman F. Nemeroff C. B. The interface of depression and cardiovascular disease: therapeutic implications. Ann N Y Acad Sci: 2015; 1345 25 35
3. Lichtman J. H. Bigger J. T. Jr. Blumenthal J. A., et al. American Heart Association Prevention Committee of the Council on Cardiovascular Nursing; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Epidemiology and Prevention; American Heart Association Interdisciplinary Council on Quality of Care and Outcomes Research; American Psychiatric Association. Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Psychiatric Association. Circulation: 2008; 118 17 1768 1775
4. Kauskot A. Hoylaerts M. F. Platelet receptors. Handb Exp Pharmacol: 2012; 210 23 57
5. Bongioanni P. Dadone F. Donato M. Human blood platelet as research tool in neuropsychopharmacology. J Neural Transm Suppl: 1991; 33 65 71
6. Ehrlich D. Humpel C. Platelets in psychiatric disorders. World J psychiatry: 2012; 2 06 91 94
7. Glassman A. H. O'Connor C. M. Califf R. M., et al. Sertraline Antidepressant Heart Attack Randomized Trial (SADHEART) Group. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA: 2002; 288 06 701 709
8. Carney R. M. Freedland K. E. Jaffe A. S., et al. Depression as a risk factor for post-MI mortality. J Am Coll Cardiol: 2004; 44 02 472 474, author reply 473-474
9. Taylor C. B. Youngblood M. E. Catellier D., et al. ENRICHD Investigators. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry: 2005; 62 07 792 798
10. Lespérance F. Frasure-Smith N. Koszycki D., et al. CREATE Investigators. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. JAMA: 2007; 297 04 367 379
11. Zafar M. U. Paz-Yepes M. Shimbo D., et al. Anxiety is a better predictor of platelet reactivity in coronary artery disease patients than depression. Eur Heart J: 2010; 31 13 1573 1582
12. Lopez-Vilchez I. Serra-Millas M. Navarro V., et al. Prothrombotic platelet phenotype in major depression: downregulation by antidepressant treatment. J Affect Disord: 2014; 159 39 45
13. Galan A. M. Lopez-Vilchez I. Diaz-Ricart M., et al. Serotonergic mechanisms enhance platelet-mediated thrombogenicity. Thromb Haemost: 2009; 102 03 511 519
14. Lopez-Vilchez I. Diaz-Ricart M. White J. G. Escolar G. Galan A. M. Serotonin enhances platelet procoagulant properties and their activation induced during platelet tissue factor uptake. Cardiovasc Res: 2009; 84 02 309 316
15. Talib L. L. Joaquim H. P. Forlenza O. V. Platelet biomarkers in Alzheimer's disease. World J Psychiatry: 2012; 2 06 95 101
16. Asor E. Ben-Shachar D. Platelets: a possible glance into brain biological processes in schizophrenia. World J Psychiatry: 2012; 2 06 124 133
17. Coughlin S. R. Thrombin signalling and protease-activated receptors. Nature: 2000; 407 (6801): 258 264
18. Fusté B. Díaz-Ricart M. Jensen M. K. Ordinas A. Escolar G. White J. G. TRAP induces more intense tyrosine phosphorylation than thrombin with differential ultrastructural features. Am J Pathol: 2002; 160 06 2245 2252
19. Diaz-Ricart M. Fuste B. Estebanell E., et al. Efficient tyrosine phosphorylation of proteins after activation of platelets with thrombin depends on intact glycoprotein Ib. Platelets: 2005; 16 08 453 461
20. Pujadas-Mestres L. Escolar G. Arellano-Rodrigo E. Galán A. M. Apixaban in the prevention of stroke and systemic embolism in nonvalvular atrial fibrillation. Drugs Today (Barc): 2013; 49 07 425 436
21. Depta J. P. Bhatt D. L. New approaches to inhibiting platelets and coagulation. Annu Rev Pharmacol Toxicol: 2015; 55 373 397
22. Shankar H. Garcia A. Prabhakar J. Kim S. Kunapuli S. P. P2Y12 receptor-mediated potentiation of thrombin-induced thromboxane A2 generation in platelets occurs through regulation of Erk1/2 activation. J Thromb Haemost: 2006; 4 03 638 647
23. Estebanell E. Diaz-Ricart M. Escolar G. Lozano M. Mazzara R. Ordinas A. Alterations in cytoskeletal organization and tyrosine phosphorylation in platelet concentrates prepared by the buffy coat method. Transfusion: 2000; 40 05 535 542
24. Serebruany V. L. Gurbel P. A. O'Connor C. M. Platelet inhibition by sertraline and N-desmethylsertraline: a possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors. Pharmacol Res: 2001; 43 05 453 462
25. Carneiro A. M. Cook E. H. Murphy D. L. Blakely R. D. Interactions between integrin alphaIIbbeta3 and the serotonin transporter regulate serotonin transport and platelet aggregation in mice and humans. J Clin Invest: 2008; 118 04 1544 1552
26. Maurer-Spurej E. Pittendreigh C. Solomons K. The influence of selective serotonin reuptake inhibitors on human platelet serotonin. Thromb Haemost: 2004; 91 01 119 128
27. Tseng Y. L. Chiang M. L. Huang T. F. Su K. P. Lane H. Y. Lai Y. C. A selective serotonin reuptake inhibitor, citalopram, inhibits collagen-induced platelet aggregation and activation. Thromb Res: 2010; 126 06 517 523
28. Tseng Y. L. Chiang M. L. Lane H. Y. Su K. P. Lai Y. C. Selective serotonin reuptake inhibitors reduce P2Y12 receptor-mediated amplification of platelet aggregation. Thromb Res: 2013; 131 04 325 332
29. Heijnen H. van der Sluijs P. Platelet secretory behaviour: as diverse as the granules... or not? J Thromb Haemost: 2015; 13 12 2141 2151
30. Hergovich N. Aigner M. Eichler H. G. Entlicher J. Drucker C. Jilma B. Paroxetine decreases platelet serotonin storage and platelet function in human beings. Clin Pharmacol Ther: 2000; 68 04 435 442
31. Blardi P. de Lalla A. Urso R., et al. Activity of citalopram on adenosine and serotonin circulating levels in depressed patients. J Clin Psychopharmacol: 2005; 25 03 262 266
32. Piubelli C. Vighini M. Mathé A. A. Domenici E. Carboni L. Escitalopram affects cytoskeleton and synaptic plasticity pathways in a rat gene-environment interaction model of depression as revealed by proteomics. Part II: environmental challenge. Int J Neuropsychopharmacol: 2011; 14 06 834 855
33. Kagaya A. Kugaya A. Hayashi T., et al. Effect of citalopram on the desensitization of serotonin-2A receptor-mediated calcium mobilization in rat glioma cells. Prog Neuropsychopharmacol Biol Psychiatry: 1996; 20 01 157 166
34. Yamaji T. Kagaya A. Uchitomi Y. Yokota N. Yamawaki S. Chronic treatment with antidepressants, verapamil, or lithium inhibits the serotonin-induced intracellular calcium response in individual C6 rat glioma cells. Life Sci: 1997; 60 11 817 823
35. Oruch R. Hodneland E. Pryme I. F. Holmsen H. Psychotropic drugs interfere with the tight coupling of polyphosphoinositide cycle metabolites in human platelets: a result of receptor-independent drug intercalation in the plasma membrane? Biochim Biophys Acta: 2008; 1778 10 2165 2176
36. Oruch R. Hodneland E. Pryme I. F. Holmsen H. In thrombin stimulated human platelets Citalopram, Promethazine, Risperidone, and Ziprasidone, but not Diazepam, may exert their pharmacological effects also through intercalation in membrane phospholipids in a receptor-independent manner. J Chem Biol: 2009; 2 02 89 103
37. White J. G. Krumwiede M. D. Escolar G. EDTA induced changes in platelet structure and function: influence on particle uptake. Platelets: 1999; 10 05 327 337
38. Zucker M. B. Grant R. A. Nonreversible loss of platelet aggregability induced by calcium deprivation. Blood: 1978; 52 03 505 513
39. Offermanns S. Activation of platelet function through G protein-coupled receptors. Circ Res: 2006; 99 12 1293 1304
40. Pleines I. Hagedorn I. Gupta S., et al. Megakaryocyte-specific RhoA deficiency causes macrothrombocytopenia and defective platelet activation in hemostasis and thrombosis. Blood: 2012; 119 04 1054 1063
41. Guinebault C. Payrastre B. Racaud-Sultan C., et al. Integrin-dependent translocation of phosphoinositide 3-kinase to the cytoskeleton of thrombin-activated platelets involves specific interactions of p85 alpha with actin filaments and focal adhesion kinase. J Cell Biol: 1995; 129 03 831 842
42. Nadal-Wollbold F. Pawlowski M. Lévy-Toledano S. Berrou E. Rosa J. P. Bryckaert M. Platelet ERK2 activation by thrombin is dependent on calcium and conventional protein kinases C but not Raf-1 or B-Raf. FEBS Lett: 2002; 531 03 475 482
43. Scalco A. Z. Rondon M. U. Trombetta I. C., et al. Muscle sympathetic nervous activity in depressed patients before and after treatment with sertraline. J Hypertens: 2009; 27 12 2429 2436
44. Barton D. A. Dawood T. Lambert E. A., et al. Sympathetic activity in major depressive disorder: identifying those at increased cardiac risk? J Hypertens: 2007; 25 10 2117 2124
45. de Abajo F. J. Effects of selective serotonin reuptake inhibitors on platelet function: mechanisms, clinical outcomes and implications for use in elderly patients. Drugs Aging: 2011; 28 05 345 367
46. Andrade C. Drug interactions in the treatment of depression in patients with ischemic heart disease. J Clin Psychiatry: 2012; 73 12 e1475 e1477
47. Thornton J. D. Agarwal P. Sambamoorthi U. Use of selective-serotonin reuptake inhibitors and platelet aggregation inhibitors among individuals with co-occurring atherosclerotic cardiovascular disease and depression or anxiety. SAGE Open Med: 2016; 4 2050312116682255